Transforming growth factor β1 expression in human colorectal tumours: An independent prognostic marker in a subgroup of poor prognosis patients

British Journal of Cancer

Volumn 74, Issue 5, 1996, Pages 753-758

  Robson, H ^a   Anderson, E ^a   James, R D ^a   Schofield, P F ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Latency associated peptide; Prognostic factor; Survival; Transforming growth factor beta 1

Indexed keywords

LATENCY ASSOCIATED PEPTIDE; PEPTIDE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CELL GROWTH; CELL TYPE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COLORECTAL TUMOR; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; SURVIVAL TIME; TUMOR CELL; TUMOR GROWTH;

EID: 0029740157     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.432     Document Type: Article

References (37)

1. ARRICK BA, LOPEZ AR, ELFMAN F, EBNER R, DAMSKY CH AND DERYNCK R. (1992). Altered metabolic and adhesive properties and increased tumourigenesis associated with increased expression of TGFβ. J. Cell Biol., 118, 715-726.
2. ARTEAGA CL, CARTYDUGGER T, MOSES HL, HURD SD AND PIETENPOL JA. (1993). TGFβ1 can induce oestrogen-independent tumourigenicity of human breast cancer cells in athymic mice. Cell Growth Differ., 4, 193-201.
3. AVERY A, PARASKEVA C, HALL P, FLANDERS KC, SPORN M AND MOORGHEN M. (1993). TGFβ expression in the human coion: differential immunostaining of the crypt epithelium. Br. J. Cancer, 68, 137-139.
4. BAIGRIE RJ AND BERRY AR. (1994). Management of advanced rectal cancer. Br. J. Surg., 81, 343-352.
5. BARCELLOS-HOFF MH, DERYNCK R, TSANG ML AND WEATHERBEE JA. (1994). Transforming growth factor-beta activation in irradiated murine mammary gland. J. Clin. Invest., 93, 892-899.
6. CHAKRABARTY S, FAN D AND VARANI J. (1990). Modulation of differentiation and proliferation in human colon carcinoma cells by TGFβ1 and TGFβ2. Int. J. Cancer, 46, 493-499.
7. CHEN RH, EBNER R AND DERYNCK R. (1993). Inactivation of the type II receptor reveals two receptor pathways for the diverse TGFβ activities. Science, 260, 1335.
8. COFFEY RJ, SHIPLEY GD AND MOSES HL. (1986). Production of TGFβ by human colon cancer cell lines. Cancer Res., 46, 1164-1169.
9. FRIESS H, YAMANAKA Y, BUCHLER M, EBERT M, BEGER HG, GOLD LI AND KORC M. (1993). Enhanced expression of TGFβ isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology, 105, 1846 1856.
10. GEISER AG, BURMESTER JK, WEBBINK R, ROBERTS AB AND SPORN MB. (1992). Inhibition of growth by TGFβ following fusion of two non-responsive human carcinoma cell lines. J. Biol. Chem., 267, 2588-2593.
11. GORSCH SM, MEMOLI VA, STUKEL TA, GOLD LI AND ARRICK BA. (1992). Immunohistochemical staining for TGFβ1 associates with disease progression in human breast cancer. Cancer Res., 52, 6949-6952.
12. HARPEL JG, METZ CN, KOJIMA S AND RIFKIN DB. (1992). Control of TGFβ activity: latency vs activation. Prog. Growth Factor Res., 4, 321-335.
13. HIRAYAMA D, FUJIMORI T, SATONAKA K, NAKAMURA T, KITAZAWA S, HORIO M, MAEDA S AND NAGASAKO K. (1992). Immunohistochemical study of EGF and TGFβ in the penetrating type of early gastric cancer. Hum. Pathol., 23, 681-686.
14. JASANI B, WYLLIE FS, WRIGHT PA, LEMOINE NR, WILLIAMS ED AND WYNFORD-THOMAS D. (1990). Immunocytochemically detectable TGFβ associated with malignancy in thyroid epithelial neoplasia. Growth Factors, 2, 149 155.
15. JASS JR. (1989). Prognostic variables in large bowel cancer. J. Clin. Pathol., 42, 1006-1007.
16. KHAN S, RAZA A, PETRELLI N AND MITTLEMAN A. (1988). In vivo determinations of labelling index of metastatic colorectal carcinoma and normal mucosu using intravenous infusion of bromodeoxyuridine. J. Surg. Oncol., 39, 114 118.
17. KOHNEWOMPNER CH, SCHOFFSKI P AND SCHMOLL HJ. (1994). Adjuvant therapy for colon adenocarcinoma current status of clinical investigation. Ann. Oncol., 5, S97 S104.
18. LAHM H AND ODARTCHENKO N. (1993). Role of TGFβ in colorectal cancer. Growth Factors, 9, 1 9.
19. LAROCCA RV, PARK JG, DANESI R, DELTACCA M, STEINBERG SM AND GAZDAR AF. (1992). Pattern of growth factor, protooncogene and CEA gene expression in human colorectal carcinoma cell lines. Oncology, 49, 209 214.
20. MCCARTNEY-FRANCIS NL AND WAHL SM. (1994). TGFβ: a matter of life and death. J. Leuk. Biol., 55, 401 409.
21. MANNING AM, WILLIAMS AC, GAME SM AND PARASKEVA C. (1991). Differential sensitivity of human colonic adenoma and carcinoma cells to TGFβ. Oncogene, 6, 1471 1476.
22. MARKOWITZ S, WANG J, MYENOFF L, PARSONS R, SUN LZ, LUTTERBAUGH J, FAN RS, ZBOROWSKA E, KINZLER KW, VOGELSTEIN B, BRATTAIN M AND WILLSON JKV. (1995). Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science, 268, 1336 1338.
23. MASSAGUE J, CHIEFETZ S, LAIHO M, RALPH DA, WEIS FMB AND ZENTELLA A. (1992). Transforming growth factorβ. Cancer Surveys, 12, 81 103.
24. MIYAZONO K, DIJKE PT, ICHIJO H AND HELDIN CH. (1994). Receptors for TGFβ. Adv. Immunol., 55, 181 221.
25. MULDER KM, LEVINE AE, HERNANDEZ X, MCKNIGHT MK, BRATTAIN DE AND BRATTAIN MG. (1988). Modulation of cmyc by TGFβ in human colon carcinoma cells. Biochem. Biophys. Res. Commun., 150, 711 716.
26. MURTHY U, ANZANO MA AND GRIEG RG. (1989). Expression of TGFαEGF and TGFα receptors in human colon carcinoma cell lines. Int. J. Cancer. 44, 110 115.
27. O'CONNELL MJ AND GUNDERSON LL. (1992). Adjuvant therapy for carcinoma of the rectum. World J. Surg., 16, 510 515.
28. ODEKON LE, BLASI F AND RIFKIN DB. (1994). Requirement for receptor bound urokinase in plasmin-dependent cellular conversion of latent TGFβ to TGFβ. J. Cell Physiol., 158, 398 407.
29. OSAMURA RJ, ODA K, HORI S, TAUCHI K, TOKUDA Y, KUBOTA M AND TAJIMA T. (1990). Evaluation of immunohistochemical expression of TGFβ as a prognostic factor for mammary carcinomas. Lab. Invest., 62, A76.
30. ROTHENBERGER DA. (1993). Relevant clinical information and tumour markers. Int. Cancer, 71, 4193 4197.
31. SCHMOLL HJ. (1994). Colorectal carcinoma current problems and future perspectives. Ann. Oncol., 5, S115 S121.
32. SCHOFIELD PE, WALSH S AND TWEEDLE DEF. (1986). Survival after treatment of carcinoma of the rectum. Br. Med. J., 293, 496-497.
33. STEINER MS AND BARRACK ER. (1992). TGFβ1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol. Endocrinol., 6, 15 25.
34. THOMPSON TC, TRUONG LD, TIMME TL, KADMON D, MCKUNE BK, FLANDERS KC, SCARDINO PT AND PARK SH. (1992). TGFβ1 as a biomarker for prostate cancer. J. Cell Biochem., 16H, 54-61.
35. WAKEFIELD LM, SMITH DM, BROZ S, JACKSON M, LEVINSON AD AND SPORN MB. (1989). Recombinant TGFβ1 synthesized as a two component latent complex that share some structural features with the native platelet latent TGFβ1 complex. Growth Factors, 1, 203 218.
36. WALKER RA AND DEARING SJ. (1992). TGFβ1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur. J. Cancer, 28A, 641-644.
37. WOLMARK N, ROCKETTE H, FISHER B, WICKERHAM DL, REDMOND C, FISHER ER, JONES J, MAMOUNAS EP, ORE L, PETRELLI NJ, SPURR CL, DIMITROV N, ROMOND EH, SUTHERLAND CM, KARDINAL CG, DEFUSCO PA AND JOCHIMSEN P. (1993). The benefit of leucovorin-modulated fluorouracil as post-operative adjuvant therapy for primary colon cancer. J. Clin. Oncol., 11, 1879 1887.